focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,088.00
Ask: 12,092.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,090.00
High: 12,118.00
Low: 12,038.00
Prev. Close: 12,110.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Japan approves Moderna and AstraZeneca vaccines

Fri, 21st May 2021 08:17

(Alliance News) - Japan formally approved the Covid-19 vaccines of Moderna Inc and AstraZeneca PLC on Friday, but the latter will not be used immediately because of lingering concern over very rare blood clots.

The decision comes just over two months before the pandemic-postponed Olympics, with growing disquiet in Japan about the country's comparatively slow vaccine rollout.

Nine regions including Tokyo are already under a virus state of emergency, with the measure now being expanded to Okinawa in the south.

Until now, only the vaccine from Pfizer Inc and BioNTech SE was available in Japan, after being approved in February, and so far just 2% of the country's 125 million residents are fully vaccinated.

In a statement, the health ministry said the two additional formulas had been approved.

But a spokesman said discussion would continue on use of the AstraZeneca vaccine "while monitoring the situation in other countries".

Only medical workers and the elderly are so far eligible for vaccines, with no timeframe yet for expanding the rollout.

Two mass vaccination centres operated by the military will open next week in Tokyo and Osaka to administer the two-shot Moderna vaccine, initially to the over-65s.

There is no timeline yet for use of the AstraZeneca jab, which some countries have restricted or dropped from their vaccine campaigns over rare blood clot concerns, even though experts say the benefits outweigh the risks.

AstraZeneca separately said its vaccine, called Vaxzevria, was approved for emergency use by the Japanese Ministry of Health, Labour & Welfare. Production of the vaccine in Japan is already underway, it said, and the first doses are expected to be available in the coming weeks.

Moderna's chief executive told the Nikkei newspaper on Friday that it was considering manufacturing the vaccine in Asia, possibly in Japan.

International Olympic Committee chief Thomas Bach said this week that at least three-quarters of athletes and team members staying at Tokyo's Olympic village will be vaccinated before the Games, which open on July 23.

Organisers insist the event can be held safely this summer, although public opinion remains largely opposed as infections surge in Japan.

Nine regions including Tokyo are currently under a virus state of emergency that runs until May 31. But recent reports have suggested the measure could be extended for a second time.

And on Friday, the southern island region of Okinawa will be added to the areas under the emergency measures for a period running from Sunday until June 20.

Japan has seen a relatively small coronavirus outbreak, with around 12,000 deaths overall, but a recent surge in infections has put hospitals under strain, medics say.

Japan has agreements with drug firms to provide enough vaccines for its entire population, including Moderna doses for 25 million people, Pfizer for 97 million people and AstraZeneca doses sufficient to vaccinate 60 million people.

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.